New axSpA Criteria: Who gets left out?
Dr. Nelly Ziade discusses abstract OP0236, OP0239, and POS0190 EULAR 2026.
Watch video →What's hot!
View all perspectives
What's Hot
What Happens when CAR-T Fails Managing Disease Recurrence
Dr. Alfred Kim discusses abstracts OP0076 and OP0333 presented at EULAR 2026.
Watch video →
‘Strong’ Treatment Predictions in Inflammatory Myositis
Dr. Janet Pope, reports on abstracts POS0264 and OP0166, presented at the 2026 EULAR meeting in London.
Watch video →
Imaging in Subclinical Psoriatic Arthritis
Dr. Antoni Chan discusses abstract OP068 presented at EULAR 2026.
Watch video →
Are we failing in the treatment of RA-ILD?
Dr. Janet Pope discusses treatment of RA-ILD after attending the "How to Treat (HOT)" session on RA-ILD at EULAR 2026.
Watch video →
PsA Potpourri: Probiotics & Head-to-Head Data
Dr. Peter Nash reports on abstracts POS0290 and LB0001 at EULAR 2026.
Watch video →
Combination Biologics in PsA: MRI Findings from AFFINITY
Dr. Artie Kavanaugh reports on abstract OP0186 presented at EULAR 2026 in London.
Watch video →
How Many CAR-Ts Do We Need to Test Drive?
Dr. Janet Pope reviews CAR-T therapy at 2026 EULAR 2026, and the issues and questions that remain with its use in rheumatology.
Watch video →
BMI Outranks Treatment in PsA Outcomes?
Dr. Peter Nash reports on abstract OP0187 presented at EULAR 2026 in London.
Watch video →
Dietary Interventions in PsA
Dr. Peter Nash reports on several abstracts at the 2026 EULAR meeting in London, including: OP069; OP070 and POS0050.
Watch video →
Low dose Blinatumomab: Many Relapse with an Unexpected Surprise
Dr. Alfred Kim discusses abstract OP0203 presented at EULAR 2026 in London.
Watch video →
RA BRIDGE and RA BRANCH trials: Baricitinib and VTE Risk
Drs. Mrinalini Dey and Jon Giles discuss abstract LB0009 presented at EULAR 2026 in London
Watch video →
Day 4 Recap: EULAR 2026
Join Drs. Jack Cush, Mrinalini Dey, Antoni Chan, and Yuz Yusof. Abstracts discussed included: LB0001 LB0002 LB0003 LB0005 LB0007 LB0009 RA Plenary POS1350.
Watch video →
EULAR 2026 Recommendations: Immunization
Dr. Jiha Lee reporting from EULAR 2026 in London.
Watch video →
Making Methotrexate More Effective
Dr. Jonathan Kay reports on abstract OP0206 and OP0207 presented at EULAR 2026 in London
Watch video →
Day 3 Recap: EULAR 2026
Join Drs. Jack Cush, Jiha Lee, Nelly Ziade, and Sheila Reyes for a lively discussion. Abstracts discussed included: OP0348 POS0290 OP0342 POS1068 POS0201 POS0288
Watch video →
5 years since Patient ID001: Progress on CAR-T Therapy in RMD
Five years on, are we closer to licensing of the first CAR-T therapy in rheumatic and musculoskeletal diseases (RMD)?
Read more →
Over 70% of patients with PsA struggle with excess weight, amplifying synovio-entheseal inflammation and blunting biologic response. The rapid uptake of GLP-1RAs in rheumatology has raised an urgent mechanistic question: are clinical gains in PsA driven purely by weight reduction, or do these agents carry intrinsic anti-inflammatory properties? EULAR 2026 offered six abstracts that together illuminate, without fully resolving, this question.
Nelly ZIADE 🍀 Nellziade
2 months 1 week ago
📈 Do SIJ lesions progress in #axSpA?
DESIR cohort (n=649, 10yrs):
Yes, slowly, but bDMARDs reduce erosion progression
#OP0102 #EULAR2026 @RheumNow https://t.co/Ap35q9D6B4
Nelly ZIADE 🍀 Nellziade
2 months 1 week ago
🔍 Best imaging outcome for #axSpA structural change?
SPACE cohort (n=332): MRI-SIJ fat lesions most sensitive to change
#OP0103 #EULAR2026 @RheumNow https://t.co/His1BGYmEW
Nelly ZIADE 🍀 Nellziade
2 months 1 week ago
🖥️ Can MRI-based synthetic CT detect spinal progression in #axSpA?
COPECARE (n=25, 1yr): sCT matches ldCT with no radiation
#OP0104 #EULAR2026 @RheumNow https://t.co/pe9wSMXXZQ
Nelly ZIADE 🍀 Nellziade
2 months 1 week ago
🔍 Is #axSpA overdiagnosed locally?
IMPROVE-axSpA prosp study (n=969):
Yes!
Only 54% locally confirmed centrally
#OP0105 #EULAR2026 @RheumNow https://t.co/VqCPbbCHLB
Nelly ZIADE 🍀 Nellziade
2 months 1 week ago
🔍Can early TNFi beat step-up csDMARDs in pSpA?
SPARTACUS RCT (n=97) says YES
60% vs 33% remission at 24 wks
#EULAR2026 @rheumnow #OP0107 https://t.co/1odtcRdTLQ
Nelly ZIADE 🍀 Nellziade
2 months 1 week ago
💉 IXE+TZP beat IXE alone in obese PsA?
YES - TOGETHER-PsA RCT
33.5% vs 20.4% ACR50 at week 36 in 271 patients
OP069 #EULAR2026 @RheumNow
@DrLauraCoates @AlexisOgdie https://t.co/orvAe38alc
Nelly ZIADE 🍀 Nellziade
2 months 1 week ago
🥗 Does diet improve PsA?
DIPSA RCT: Mediterranean/DASH/Standard all improved DAPSA in 92pts
Weight loss drove outcomes
OP070 #EULAR2026 @RheumNow https://t.co/k5y7bvDbDQ
sheila RHEUMarampa
2 months 1 week ago
Results of this 10yr ffup study on impact of sex on clinical outcomes & spinal xray prog in SpA:
Females ⬆️ dse act (asdas,basdai) ⬆️enthesitis scores, S/TJCts
Males ⬆️rate of xray prog(msasss)
Sex diffs exist in SpA
Need for sex-specific mgt
AbsOP0101 @Rheumnow #EULAR2026 https://t.co/qiNzDFh08v
Md Yuzaiful Md Yusof Yuz6Yusof
2 months 1 week ago
#EULAR2026 OP028 In 16 patients with AID (SSc,IIM, RA, IgG4,SjD, Grave’s), CD3xBCMA BiTE, Teclistamab was effective in 15/16. Duration of GC & DMARD-free was 11 mths. 2/16 need retreatment. All had low IgG and needed IVIG. Need long-term safety data & comparative study @RheumNow https://t.co/97MUPnXRua
Dr. John Cush RheumNow
2 months 1 week ago
The first two days of EULAR 2026 have delivered a flood of new data, late-breaking science, and clinical insights. Don't spend hours sorting through hundreds of abstracts; RheumNow will do it for you.
Join Dr. Jack Cush and https://t.co/V10S4oVFsv faculty as they break down the https://t.co/eAPV6h5FAn
Nelly ZIADE 🍀 Nellziade
2 months 1 week ago
♂♀ Does sex matter in #axSpA long-term?
GESPIC (n=525,10y):
Yes! ♂ less symptoms but 2x more spinal progression
#OP0101 #EULAR2026 @RheumNow https://t.co/znFXWyrfZl
Nelly ZIADE 🍀 Nellziade
2 months 1 week ago
🔍 What defines a positive MRI for #axSpA?
SPARTAN-SSR consensus (n=1,050):
BME≥3 slices or 2/3 lesions in ≥3 SIJ quadrants
#OP0100 #EULAR2026 @RheumNow https://t.co/nfhzGxBZOm
Nelly ZIADE 🍀 Nellziade
2 months 1 week ago
HLA-Cw6: a marker of more severe and difficult to manage psoriatic arthritis?
POS0484
#EULAR2026
@RheumNow https://t.co/MIYZxuYT4v
sheila RHEUMarampa
2 months 1 week ago
Interesting pilot study using line-field confocal OCT for CLE
The “virtual biopsy” identified distinct layer-specific patterns across diff CLE subtypes including distinctions
bet ACLE & rosacea (dil. vessels, demodex mites, periannexal infil)
AbsOP099 @RheumNow #EULAR2026 https://t.co/yQSc6u4oYV
